Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SPY003
SPY003-207 · 1 trial · 1 indication
Incidence, severity, and causal relationship of TEAEs
| Arm | Type | Description |
|---|---|---|
| SAD Cohorts 1-6 Experimental Arm | EXPERIMENTAL | Participants will receive a single dose of SPY003-207 in a dose escalation format |
| SAD Cohorts 1-6 Placebo Arm | PLACEBO_COMPARATOR | Participants will receive a single dose of placebo |
| SAD Cohort 7, Experimental Arm | EXPERIMENTAL | Participants of Chinese descent will receive a single dose of SPY003-207-101 |
| SAD Cohort 7, Placebo Arm | PLACEBO_COMPARATOR | Participants of Chinese descent will receive a single dose of placebo |
| MAD Cohorts 1 Experimental Arm | EXPERIMENTAL | Participants will receive two doses of SPY003-207-101 in a dose escalation format |
| MAD Cohorts 1 Placebo Arm | PLACEBO_COMPARATOR | Participants will receive two doses of placebo |
| Name | Type | Description |
|---|---|---|
| SPY003-207 | DRUG | Experimental |
| Placebo | OTHER | Placebo |
Inclusion Criteria: * Healthy men and women * Willing and able to attend the necessary visits to the CRU, comply with all testing requirements, remain at the study site unit for the duration of the confinement period and return for the outpatient visits Exclusion Criteria: * Participation in more...
SPY003-207 is an investigational small molecule being developed by Spyre Therapeutics, Inc. It is in Phase 1 clinical development and is being studied in healthy adult volunteers. Spyre Therapeutics trades on the Nasdaq under the ticker SYRE.
SPY003-207 targets IL-23p19. IL-23p19 is a subunit of the interleukin-23 cytokine, and targeting it is a mechanism used to modulate IL-23 signaling. SPY003-207 is a small molecule directed at this target.
Spyre Therapeutics, Inc. is developing SPY003-207. The company is publicly traded on the Nasdaq under the ticker symbol SYRE. Spyre Therapeutics is the sponsor of the clinical program for this asset.
SPY003-207 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The program currently has one active Phase 1 trial, with no completed trials reported.
SPY003-207 is being studied in the Phase 1 trial NCT06873724, titled A Study of SPY003-207 in Healthy Volunteers. The trial is active but not recruiting, is randomized, double blind, and placebo controlled, and plans to enroll 59 participants in the United States and Canada.
The Phase 1 trial NCT06873724 for SPY003-207 enrolls healthy adult volunteers. Participants must be 18 years of age or older, and both sexes are eligible. The study is being conducted at sites in the United States and Canada.